PATENT CLAIM ANALYSIS

Application Number: 16190869
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "312000"]

Abstract:
The invention relates to administration of various pharmaceutical formulations of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (cabozantinib) a c-Met inhibitor, and its metabolites, to achieve desirable pharmacokinetic and pharmacodynamic effects.

Claim (Index 9):
The method of  claims 5 - 8 , wherein the cancer is selected from ovarian cancer, lung cancer, medullary thyroid cancer, liver cancer, gastrointestinal cancer, pancreatic cancer, bone cancer, hematologic cancer, skin cancer, kidney cancer, breast cancer, colon cancer, and fallopian tube cancer.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 98.0
- Lexical Diversity: 1.28205
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15126767', '10706328', '14776337', '12845600', '13714246']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7564787485406644
- 35 USC 102 Novelty (BERT): 0.5974684803713683
- Combined Prediction Score: 0.7405777217237348
- Mean Citation Score: 328.67702799999995
- Max Citation Score: 562.41516
- Similarity Product: 408.91001325422286

Labels:
- Claim Label 101: 0
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test